Advertisement
MDT vs SYK
Which Stock Would AI Choose? Medtronic (MDT) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Both MDT and SYK operate in the medical devices sector, with MDT emphasizing broad cardiovascular and neuroscience portfolios while SYK focuses on orthopedics and surgical technologies.
- Recent market activity shows MDT with stronger month-over-month gains near 6% amid analyst price target increases and upcoming earnings, compared to SYK’s more mixed post-earnings performance.
- MDT reported robust organic revenue growth in its most recent quarter, driven by new product launches in high-growth areas like cardiac ablation.
- SYK demonstrated solid double-digit organic sales growth in its latest quarter while recovering from prior operational disruptions.
- Valuation metrics indicate MDT trades at a lower forward price-to-earnings ratio than SYK, reflecting differing growth profiles and market positioning.
- Sector tailwinds from aging populations and innovation pipelines support both companies, though execution on product cycles and margin pressures remain key differentiators.
Introduction
Medtronic (MDT) and Stryker (SYK) represent two leading players in the medical devices industry, offering investors exposure to healthcare innovation and demographic-driven demand. This comparison examines their business models, recent performance trends, and relative positioning in the current market environment. The analysis targets experienced traders monitoring sector rotations and newer investors seeking objective data on established healthcare equities. By focusing on verifiable metrics such as revenue growth, analyst sentiment, and operational developments over recent weeks, the review highlights contrasts that may inform portfolio allocation decisions without favoring either security.
MDT Overview and Recent Performance
Medtronic plc designs, manufactures, and markets a wide range of medical devices across cardiovascular, medical-surgical, neuroscience, and diabetes segments. In recent market activity, MDT shares have shown resilience, posting approximately 6% gains over the past month amid positive analyst commentary and anticipation of first-quarter fiscal 2027 results. Key developments include sustained momentum in the Cardiovascular business, with strong contributions from cardiac ablation solutions and new product platforms such as pulsed field ablation and the Hugo surgical robot. The company delivered its highest revenue growth in ten quarters in its most recent reported period, supported by organic expansion and international demand. Broader sentiment has benefited from raised price targets from firms including Needham, reflecting confidence in the ongoing product cycle despite ongoing tariff-related cost pressures.
SYK Overview and Recent Performance
Stryker Corporation develops and sells medical technologies focused on orthopedics, medical and surgical equipment, and neurotechnology. Over recent weeks, SYK shares have traded with some volatility following its second-quarter 2026 earnings release, which featured 9% organic sales growth and an adjusted earnings beat. The company highlighted recovery from a prior cybersecurity incident, with improved production and strong demand for its Mako robotic system and other capital equipment. Guidance for full-year 2026 was narrowed modestly while remaining positive, citing continued innovation and operational execution. Market positioning has been influenced by broader sector dynamics and institutional activity, with the stock reflecting both the benefits of volume-driven growth and sensitivity to supply chain normalization.
Trending AI Robots
Tickeron maintains a curated selection of AI-powered trading bots on its platform, drawing from hundreds of available strategies that cover thousands of tickers across diverse market conditions. Only those demonstrating the strongest alignment with prevailing trends, risk-adjusted performance, and adaptability earn placement in the Trending AI Robots section. Available bots exhibit varied trading styles, timeframes, and statistical profiles, with many reporting win rates and return metrics that reflect their specific approaches to equity and sector exposure. This section provides traders with transparent access to performance data and strategy details. For more information, visit Trending AI Robots.
Head-to-Head Comparison
Medtronic operates a diversified portfolio spanning multiple therapeutic areas, providing broader exposure to cardiovascular innovation compared with Stryker’s concentrated strength in orthopedics and robotic-assisted surgery. Growth drivers differ accordingly: MDT benefits from accelerated adoption of ablation and neuromodulation technologies, while SYK leverages procedure volume in joint replacements and trauma. Recent momentum favors MDT following successive quarters of above-guidance organic growth and analyst upgrades, whereas SYK has demonstrated recovery but faced post-earnings share pressure. Risk factors include MDT’s exposure to global tariffs and restructuring costs versus SYK’s operational normalization following the cyber event. Market sentiment reflects these contrasts, with valuation multiples showing MDT at a discount on a forward earnings basis relative to SYK’s premium positioning.
Tickeron AI Verdict
Based on observable factors including recent trend consistency in organic growth, analyst sentiment shifts, and product cycle visibility, Tickeron’s AI models currently assign a probabilistic edge to MDT over SYK in the near term. The assessment incorporates stability metrics around earnings delivery and relative positioning within the medical devices sector, though outcomes remain subject to broader market conditions and execution variables.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDT is a StrongBuy and SYK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDT’s FA Score shows that 2 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- MDT’s FA Score: 2 green, 3 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDT’s TA Score shows that 4 TA indicator(s) are bullish while SYK’s TA Score has 4 bullish TA indicator(s).
- MDT’s TA Score: 4 bullish, 4 bearish.
- SYK’s TA Score: 4 bullish, 6 bearish.
Price Growth
MDT (@Medical/Nursing Services) experienced а +3.22% price change this week, while SYK (@Medical/Nursing Services) price change was -8.33% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.20%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -5.15%.
Reported Earning Dates
MDT is expected to report earnings on Nov 24, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical/Nursing Services (-4.20% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| MDT | SYK | MDT / SYK | |
| Capitalization | 120B | 116B | 103% |
| EBITDA | 10.3B | 6.97B | 148% |
| Gain YTD | -0.275 | -13.289 | 2% |
| P/E Ratio | 23.19 | 31.41 | 74% |
| Revenue | 37.5B | 25.8B | 145% |
| Total Cash | 8.82B | 3.48B | 254% |
| Total Debt | 28.2B | 14.9B | 189% |
MDT | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 69 | |
SMR RATING 1..100 | 68 | 53 | |
PRICE GROWTH RATING 1..100 | 29 | 63 | |
P/E GROWTH RATING 1..100 | 56 | 87 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (4) in the Medical Specialties industry is in the same range as SYK (7). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (69) in the Medical Specialties industry is in the same range as MDT (100). This means that SYK’s stock grew similarly to MDT’s over the last 12 months.
SYK's SMR Rating (53) in the Medical Specialties industry is in the same range as MDT (68). This means that SYK’s stock grew similarly to MDT’s over the last 12 months.
MDT's Price Growth Rating (29) in the Medical Specialties industry is somewhat better than the same rating for SYK (63). This means that MDT’s stock grew somewhat faster than SYK’s over the last 12 months.
MDT's P/E Growth Rating (56) in the Medical Specialties industry is in the same range as SYK (87). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
| MDT | SYK | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 57% | 4 days ago 76% |
| Stochastic ODDS (%) | 4 days ago 53% | 4 days ago 64% |
| Momentum ODDS (%) | 4 days ago 57% | 4 days ago 54% |
| MACD ODDS (%) | 4 days ago 59% | 4 days ago 44% |
| TrendWeek ODDS (%) | 4 days ago 55% | 4 days ago 52% |
| TrendMonth ODDS (%) | 4 days ago 50% | 4 days ago 52% |
| Advances ODDS (%) | 4 days ago 53% | 28 days ago 56% |
| Declines ODDS (%) | 14 days ago 57% | 4 days ago 52% |
| BollingerBands ODDS (%) | 4 days ago 61% | 4 days ago 55% |
| Aroon ODDS (%) | 4 days ago 36% | 4 days ago 54% |
Advertisement
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.